Extract from the article below:
So why should Dimerix holders be reassured?
Apart from the company’s positive interim data readout, Webster says the four global partners all underwent extensive due diligence.“Dimerix has good validation of the asset, both technically and commercially,” she says.“We have already demonstrated a strong safety profile and have collected encouraging efficacy data, across both the phase II trial and the first unblinded clinical analysis of the phase III trial.”
https://**promotion blocked**/health/dr-borehams-crucible-the-wheels-keep-turning-for-dimerix-and-its-kidney-drug-candidate/
Extract from the article below:So why should Dimerix holders be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.035(6.25%) |
Mkt cap ! $308.6M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 57.0¢ | 52.0¢ | $1.033M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18732 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 30517 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |